Inj risankizumab-rzaa 1 mg
Products billed under this code include Skyrizi.
Payment limit per 1 MG, by effective quarter, 1Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Skyrizi.
Payment limit per 1 MG, by effective quarter, 1Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Skyrizi | AbbVie Inc. | 00074-5015-01 | 600 | $8,406.60 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $14.011 | −$0.52 | 1 MG | Inj risankizumab-rzaa 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $14.531 | −$0.068 | 1 MG | Inj risankizumab-rzaa 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $14.599 | −$0.333 | 1 MG | Inj risankizumab-rzaa 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $14.932 | −$0.009 | 1 MG | Inj risankizumab-rzaa 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $14.941 | +$0.101 | 1 MG | Inj risankizumab-rzaa 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $14.84 | −$0.019 | 1 MG | Inj risankizumab-rzaa 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $14.859 | −$0.222 | 1 MG | Inj risankizumab-rzaa 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $15.081 | +$0.449 | 1 MG | Inj risankizumab-rzaa 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $14.632 | −$0.354 | 1 MG | Inj risankizumab-rzaa 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $14.986 | −$0.017 | 1 MG | Inj risankizumab-rzaa 1 mg | v1, posted June 11, 2025 |
| 2Q24 | $15.003 | −$0.36 | 1 MG | Inj risankizumab-rzaa 1 mg | v1, posted March 11, 2025 |
| 1Q24 | $15.363 | +$0.031 | 1 MG | Inj risankizumab-rzaa 1 mg | v1, posted December 19, 2024 |
| 4Q23 | $15.332 | −$0.187 | 1 MG | Inj risankizumab-rzaa 1 mg | v1, posted October 10, 2024 |
| 3Q23 | $15.519 | −$0.213 | 1 MG | Inj risankizumab-rzaa 1 mg | v1, posted June 5, 2024 |
| 2Q23 | $15.732 | −$0.077 | 1 MG | Inj risankizumab-rzaa 1 mg | v1, posted February 23, 2024 |
| 1Q23 | $15.809 | – | 1 MG | Inj risankizumab-rzaa 1 mg | v1, posted December 6, 2023 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.